Ashley Chan

Articles

2024 FDA Approvals Highlight New Treatment Considerations in HR+ Breast Cancer

January 22nd 2025

Eric Winer, MD, discusses the significance of 2 FDA approvals for HR-positive, HER2-negative breast cancer and emerging novel breast cancer treatments.

AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer

January 20th 2025

Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.

FDA Grants Orphan Drug Designation to ELC-100 for Pancreatic NETs

January 20th 2025

ELC-100 has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic neuroendocrine tumors.

Retrospective Study Highlights Real-World Uptake of Bispecific Antibodies in R/R Multiple Myeloma

January 19th 2025

Ira Zackon, MD, discusses real-world observational data on bispecific antibody use in community oncology in patients with relapsed/refractory multiple myeloma.

Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma

January 16th 2025

The FDA granted breakthrough therapy designation to lete-cel for patients with unresectable or metastatic myxoid/round cell liposarcoma.

Addition of ASCT to Ibrutinib Plus Rituximab Does Not Confer Benefit in Lower-Risk, Younger MCL

January 16th 2025

Martin Dreyling, MD, PhD, discusses the role of ASCT with or without an ibrutinib-based regimen in younger patients with mantle cell lymphoma.

Nivolumab Plus Gemcitabine/Cisplatin Shows Favorable OS/PFS Trend in Asian Unresectable/Metastatic Urothelial Cancer Subpopulation

January 15th 2025

First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.

EMA Grants Orphan Medical Product Designation to Elraglusib in Advanced PDAC

January 11th 2025

An orphan medicinal product designation was granted to elraglusib by the EMA for patients with advanced pancreatic ductal adenocarcinoma.

Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung

January 10th 2025

Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.

Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome

January 9th 2025

Duvelisib plus venetoclax was active in relapsed/refractory CLL and Richter syndrome with high-risk, TP53-aberrant disease after BTK inhibition.

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC

January 8th 2025

Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL

January 7th 2025

Armin Ghobadi, MD, discusses the safety profile of WT-7 in heavily pretreated relapsed/refractory T-ALL and LBL.

Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL

January 6th 2025

Dasom (Caroline) Lee, MD, discusses real-world data for second-line axi-cel in relapsed/refractory large B-cell lymphoma.

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer

December 16th 2024

Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.

ICIs Result in Increased Rates of High-Grade irAEs for Older Patients With Breast Cancer

December 14th 2024

The risk of developing high-grade immune-related AEs was heightened among patients with breast cancer who were older and who had chronic kidney disease.

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia

December 12th 2024

Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies

December 9th 2024

Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

November 21st 2024

James J. Harding, MD, discusses how immunotherapy could play a role in earlier stages in hepatocellular carcinoma.

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers

November 14th 2024

Sacituzumab tirumotecan monotherapy demonstrated antitumor activity with a manageable safety profile in previously treated endometrial and ovarian cancers.

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

November 9th 2024

David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.